(2026) Q&A
1. Which of the following best describes the mechanism of action of angiotensin-
converting enzyme (ACE) inhibitors?
A) Blocking the angiotensin II receptor on blood vessels
B) Inhibiting the conversion of angiotensin I to angiotensin II
C) Blocking the beta-adrenergic receptors in the heart
D) Preventing calcium from entering vascular smooth muscle cells
Correct Answer: B) Inhibiting the conversion of angiotensin I to angiotensin II
Rationale: ACE inhibitors work by blocking the ACE enzyme, which prevents the
conversion of angiotensin I to the potent vasoconstrictor angiotensin II. This leads to
vasodilation and decreased blood pressure. ARBs block the receptor directly, beta-
blockers act on the heart, and calcium channel blockers prevent calcium influx.
2. A 55-year-old African American male with stage 2 hypertension is being treated.
According to JNC 8 guidelines, which medication class is recommended as a first-line
agent for this patient?
A) Beta-blocker
B) ACE inhibitor
C) Thiazide diuretic
D) Alpha-blocker
Correct Answer: C) Thiazide diuretic
,Rationale: JNC 8 guidelines recommend thiazide diuretics, calcium channel blockers,
or ACE inhibitors/ARBs as first-line agents for the general population. However, for
African American patients, thiazide diuretics or calcium channel blockers are
preferred initial therapies due to their demonstrated efficacy in this population.
3. What is the primary mechanism of action of statins in lowering cholesterol?
A) Inhibiting the absorption of cholesterol in the small intestine
B) Inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis
C) Increasing the excretion of bile acids
D) Activating the LDL receptor on hepatocytes
Correct Answer: B) Inhibiting HMG-CoA reductase, the rate-limiting enzyme in
cholesterol synthesis
Rationale: Statins (HMG-CoA reductase inhibitors) competitively inhibit HMG-CoA
reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate.
This is the rate-limiting step in cholesterol synthesis, leading to decreased
intracellular cholesterol and upregulation of LDL receptors.
4. A patient on atorvastatin reports muscle aches and dark-colored urine. Which
laboratory test is most important to evaluate for a potential serious adverse effect?
A) Liver function tests (ALT/AST)
B) Creatine kinase (CK) level
C) Serum creatinine
D) Complete blood count (CBC)
Correct Answer: B) Creatine kinase (CK) level
, Rationale: Muscle aches with dark urine are signs of rhabdomyolysis, a serious
statin-related adverse effect. Creatine kinase (CK) is an enzyme released from
damaged muscle tissue. An elevated CK level confirms muscle damage and requires
statin discontinuation to prevent acute kidney injury.
5. A patient with heart failure is prescribed digoxin. What is the therapeutic range for
digoxin when used for heart failure?
A) 0.5 to 2.0 ng/mL
B) 0.8 to 2.0 ng/mL
C) 1.0 to 2.5 ng/mL
D) 1.5 to 3.0 ng/mL
Correct Answer: A) 0.5 to 2.0 ng/mL
Rationale: Digoxin has a narrow therapeutic index. For heart failure, the therapeutic
range is 0.5 to 2.0 ng/mL. Levels above this range significantly increase the risk of
toxicity, which can manifest as nausea, visual disturbances, and cardiac arrhythmias.
6. A patient with NYHA Class II heart failure and a reduced ejection fraction is being
started on a beta-blocker. Which of the following beta-blockers has the strongest
evidence for mortality reduction in heart failure?
A) Metoprolol tartrate
B) Atenolol
C) Carvedilol
D) Propranolol
Correct Answer: C) Carvedilol